We are proud to announce that Innovative Analytics (IA) and LBR Regulatory & Clinical (LBR) have joined forces to form LBRIA effective Oct. 10, 2025.

LBR and IA have collaborated on multiple projects for over a decade and will carry that cohesiveness into our merger. Together, we are a full-service contract research organization (CRO) designed to guide bio-pharmaceutical companies through the complex FDA drug approval process, from pre-clinical stages, through Phase 1 – 3 trials, and finally to New Drug Application (NDA) submission.

Established in 2003, IA’s greatest strength lies in biostatistics, data management, medical writing, and quality assurance expertise. Prior to the merger, it was able to support a range of needs, from proof of concept to Phase 3 studies.

LBR prides itself on providing full clinical trial services and strategic planning to see your project from initial strategy to submission for market approval. The team’s expertise in regulatory and GCP requirements has contributed to the organization’s success.

Through this merger, LBR’s robust regulatory and clinical trial management services are enhanced by IA’s deep analytical and statistical capabilities. Now joined as LBRIA, sponsors benefit from the comprehensive expertise of both teams under one collaborative and experienced umbrella.

Whether you need a full-service team to execute your clinical trial or stand-alone support in any aspect of drug development, LBRIA is ready to assist.

Please reach out if you have any questions about the merger or how LBRIA’s expanded services can help your project move forward!